Adverum Biotechnologies, Inc. (ADVM) News

Adverum Biotechnologies, Inc. (ADVM): $1.06

-0.02 (-1.85%)

POWR Rating

Component Grades













Add ADVM to Watchlist
Sign Up

Industry: Biotech


of 396

in industry

Filter ADVM News Items

ADVM News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

ADVM News Highlights

  • For ADVM, its 30 day story count is now at 6.
  • Over the past 8 days, the trend for ADVM's stories per day has been choppy and unclear. It has oscillated between 1 and 5.
  • AGE, DRUG and GENE are the most mentioned tickers in articles about ADVM.

Latest ADVM News From Around the Web

Below are the latest news stories about Adverum Biotechnologies Inc that investors may wish to consider to help them evaluate ADVM as an investment opportunity.

Insiders who bought in the last 12 months lose an additional US$367k as Adverum Biotechnologies, Inc. (NASDAQ:ADVM) drops to US$136m

The recent price decline of 12% in Adverum Biotechnologies, Inc.'s ( NASDAQ:ADVM ) stock may have disappointed insiders...

Yahoo | February 15, 2022

Adverum Biotechnologies Appoints Richard Beckman M.D. as Chief Medical Officer

- Dr. Beckman, a board-certified ophthalmologist, brings 30 years of experience in ophthalmology, drug development and retinal diseases including wet age-related macular degeneration -

GlobeNewswire | February 7, 2022

Adverum Biotechnologies names new CMO

Adverum Biotechnologies (ADVM) has appointed ophthalmologist Richard Beckman, M.D., as the company''s new chief medical officer. Most recently, Dr

Seeking Alpha | February 7, 2022

Thinking about buying stock in Jaguar Health, Evofem Biosciences, Adverum Biotechnologies, FREYR Battery, or Planet Labs?

NEW YORK , Jan. 12, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for JAGX, EVFM, ADVM, FREY, and PL. Full story available on

Benzinga | January 12, 2022

Adverum Biotechnologies Appoints Star Seyedkazemi, Pharm.D. as Chief Development Officer

REDWOOD CITY, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced that Star Seyedkazemi, Pharm.D., joined Adverum as the company’s chief development officer. Dr. Seyedkazemi will serve as a member of Adverum’s executive committee and will report to Laurent Fischer, M.D., president and chief executive officer at Adverum Biotechnologies. Dr. Seyedkaze

Yahoo | January 6, 2022

Adverum Biotechnologies Granted Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone Monochromacy

- ADVM-062 is designed as a potential treatment for blue cone monochromacy (X-linked incomplete achromatopsia) -REDWOOD CITY, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate being developed as a potentia

Yahoo | January 4, 2022

Adverum Biotechnologies (NASDAQ:ADVM) investors are sitting on a loss of 84% if they invested a year ago

It's not a secret that every investor will make bad investments, from time to time. But it's not unreasonable to try to...

Yahoo | January 1, 2022

Comparing Acumen Pharmaceuticals (NASDAQ:ABOS) and Adverum Biotechnologies (NASDAQ:ADVM)

Adverum Biotechnologies (NASDAQ:ADVM) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership. Valuation and Earnings This table compares Adverum Biotechnologies and Acumen Pharmaceuticals revenue, earnings per share []

Transcript Daily | December 24, 2021

Adverum Biotechnologies (NASDAQ:ADVM) Lifted to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Adverum Biotechnologies (NASDAQ:ADVM) from a hold rating to a buy rating in a research note released on Monday morning, reports. They currently have $2.00 target price on the biotechnology companys stock. According to Zacks, Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ocular and []

Transcript Daily | December 24, 2021

Zacks: Analysts Expect Adverum Biotechnologies, Inc. (NASDAQ:ADVM) to Announce -$0.42 EPS

Analysts expect that Adverum Biotechnologies, Inc. (NASDAQ:ADVM) will report earnings of ($0.42) per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Adverum Biotechnologies earnings, with the lowest EPS estimate coming in at ($0.43) and the highest estimate coming in at ($0.41). Adverum Biotechnologies reported earnings per share []

Transcript Daily | December 23, 2021

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.5199 seconds.